tiprankstipranks
GSK raises 2024 core EPS growth view to 8%-10% from 6%-9%
PremiumThe FlyGSK raises 2024 core EPS growth view to 8%-10% from 6%-9%
3d ago
GSK reports Q1 core EPS 43.1p, up 28% at CER
PremiumThe Fly
GSK reports Q1 core EPS 43.1p, up 28% at CER
3d ago
GSK Pharma call volume above normal and directionally bullish
PremiumThe Fly
GSK Pharma call volume above normal and directionally bullish
3d ago
CureVac, GSK announce start of Phase 1 part of investigational H5N1 trial
PremiumThe FlyCureVac, GSK announce start of Phase 1 part of investigational H5N1 trial
10d ago
CureVac announces start of Phase 1/2 study in avian influenza
PremiumThe Fly
CureVac announces start of Phase 1/2 study in avian influenza
10d ago
GSK: FDA accepts expanded Jemperli indication application for priority review
PremiumThe Fly
GSK: FDA accepts expanded Jemperli indication application for priority review
10d ago
GSK’s Shingrix Vaccine Proves Long-term Efficacy
PremiumCompany AnnouncementsGSK’s Shingrix Vaccine Proves Long-term Efficacy
17d ago
GSK’s New Antibiotic Shows High Success Rate
PremiumCompany Announcements
GSK’s New Antibiotic Shows High Success Rate
17d ago
GSK announces data from the ZOSTER-049 long-term phase III trial of Shingrix
PremiumThe Fly
GSK announces data from the ZOSTER-049 long-term phase III trial of Shingrix
17d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100